Institut d'Investigació Sanitària Illes Balears (IdISBa) Research Group.

Evaluation of Ceftolozane-Tazobactam in Combination with Meropenem against Pseudomonas aeruginosa ST175 in a Hollow-Fiber Infection Model.

Montero M1, VanScoy BD2, López-Causapé C3, Conde H2, Adams J2, Segura C4, Zamorano L3, Oliver A3, Horcajada JP5, Ambrose PG2,6.

1Infectious Diseases Service, Hospital del Mar, Infectious Pathology and Antimicrobials Research Group (IPAR), Institut Hospital del Mar d’ Investigacions Mèdiques (IMIM), Universitat Autònoma de Barcelona (UAB), CEXS-Universitat Pompeu Fabra Barcelona, Spain.
2Institute for Clinical Pharmacodynamics, Schenectady, New York, United States of America.
3Servicio de Microbiología and Unidad de Investigación, Hospital Son Espases, IdISBa, Palma de Mallorca, Mallorca, Spain.
4Laboratorio de Referencia de Catalunya, Barcelona, Spain.
5Infectious Diseases Service, Hospital del Mar, Infectious Pathology and Antimicrobials Research Group (IPAR), Institut Hospital del Mar d’ Investigacions Mèdiques (IMIM), Universitat Autònoma de Barcelona (UAB), CEXS-Universitat Pompeu Fabra Barcelona, Spain.
6University of Oxford, Oxford, United Kingdom.

The aim of this study was to investigate the efficacy of ceftolozane-tazobactam in combination with meropenem against an extensively drug-resistant (XDR) Pseudomonas aeruginosa high-risk clone, ST175, isolated in a Spanish university hospital. A 14-day hollow-fiber infection model was used to simulate clinical exposure of the 2 drug regimens alone and in combination, and serial samples were collected to determine drug concentrations and colony-forming unit (CFU) counts. The untreated control failed, as did each study regimen when administered alone. However, when ceftolozane-tazobactam was administered in combination with meropenem, there was a >4log10 CFU/ml bacterial density reduction and suppression of resistance for the duration of the study. These data suggest that ceftolozane-tazobactam plus meropenem may be a useful combination for treating XDR P. aeruginosa.

Antimicrobial Agents and Chemotherapy 2018. DOI:10.1128/AAC.00026-18

Link to Pubmed

Tagged as: , , , ,

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

ARPBIG IdISBa

Dr. Bartolome Moyà

Instituto de Investigación Sanitaria Illes Balears

Gabriel Torrens

%d bloggers like this: